(Q35140288)

6 August 2017

title

S-1 in gastric cancer: a comprehensive review (English)

1 reference

6 August 2017

1

Yoshihiko Maehara

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

6 Suppl 1

1 reference

6 August 2017

page(s)

2-8

1 reference

https://scigraph.springernature.com/pub.10.1007/s10120-003-0232-9

6 August 2017

exact match

0 references

cites work

Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcomas in rats.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10120-003-0232-9

Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10120-003-0232-9

Current strategies in the management of locoregional and metastatic gastric carcinoma

21 January 2018

1 reference

12 December 2020

Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts

1 reference

12 December 2020

Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer

1 reference

12 December 2020

Unusual survival for more than 2 years with peritoneal metastases of gastric cancer

1 reference

12 December 2020

Advanced gastric carcinoma successfully treated with TS-1 as neoadjuvant chemotherapy

1 reference

12 December 2020

Complete response achieved following administration of S-1 in a patient with adrenal gland metastasis of 5-FU-resistant gastric cancer: a case report

1 reference

12 December 2020

[Phase I study of S-1. S-1 Study Group]

1 reference

12 December 2020

Chemotherapy of gastric cancer

1 reference

12 December 2020

[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A)]

1 reference

12 December 2020

[Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)]

1 reference

12 December 2020

Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer

1 reference

12 December 2020

Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer

1 reference

12 December 2020

An oral anticancer drug, TS-1, enabled a patient with advanced gastric cancer with Virchow's metastasis to receive curative resection

1 reference

12 December 2020

Continuous 5-Fluorouracil Infusion in Advanced Gastric Carcinoma

1 reference

12 December 2020

An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)

1 reference

12 December 2020

Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells

1 reference

12 December 2020

Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group

1 reference

12 December 2020

New directions in the treatment of colorectal cancer: a look to the future

1 reference

12 December 2020

Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function

1 reference

12 December 2020

Uracil-tegafur in gastric carcinoma: a comprehensive review.

1 reference

12 December 2020

Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats

1 reference

12 December 2020

Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts

1 reference

12 December 2020

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

1 reference

12 December 2020

Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats

1 reference

12 December 2020

Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

1 reference

12 December 2020

5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development

1 reference

12 December 2020

An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group

1 reference

12 December 2020

[Phase II study with cisplatin in advanced stomach and colon carcinoma. Cooperative Study Group of Cisplatin for Stomach and Colon Carcinoma]

1 reference

12 December 2020

[Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]

1 reference

12 December 2020

Advanced gastric cancer with liver metastases successfully treated with S-1.

1 reference

12 December 2020

Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination.

1 reference

12 December 2020

Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group

1 reference

12 December 2020

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

1 reference

12 December 2020

Latest progress on chemotherapy for advanced gastric cancer

1 reference

12 December 2020

Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report

1 reference

12 December 2020

[Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study]

1 reference

12 December 2020

Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.

1 reference

12 December 2020

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

1 reference

12 December 2020

[A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B)]

1 reference

12 December 2020

Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug

1 reference

12 December 2020

Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

1 reference

12 December 2020

Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil

1 reference

12 December 2020

Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions

1 reference

12 December 2020

10.1007/S10120-003-0232-9

Identifiers

DOI

1 reference

6 August 2017

1 reference